New immune oncology drug molecules expected to result from leadXpro / InterAx partnership

Wednesday, April 18, 2018 @ 12:00 am

See the media release below on leadXpro AG and InterAx Biotech AG, joining forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Allegria Therapeutics secures USD 5.1 million seed extension financing

Allegria Therapeutics (ALLEGRIA), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today the successful completion of a USD 5.1 million seed extension financing.
December 11, 2025

ten23 health supports commercial product testing for US customers following FDA approvals

ten23 health, the human-centric and sustainable CDMO partner of choice for the pharmaceutical and biotechnology industries, today announced that its recently established and Swissmedic approved Quality Control (QC) laboratories in both Basel and Visp, Switzerland, have been formally approved by the U.S. Food and Drug Administration (FDA). The approval was granted in connection with registering ten
December 9, 2025

Cosmo flash update: Strong Breezula phase 3 results

December 5, 2025

Neurimmune expands collaboration with AstraZeneca to treat light chain amyloidosis

Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009, a preclinical human monoclonal antibody designed to target and deplete lambda light chain fibrils and deposits from affected tissues and organs in light c
December 4, 2025

Aurealis Therapeutics: Tripling complete wound closure rate in patients with chronic diabetic foot ulcers

Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of "DIAMEND" Phase-2 Randomized Controlled Trial (NCT06111183 / EU CT 2022-502048-10-00) with AUP-16, a multi-targeting cell & gene therapy for DFUs and other chronic wounds. Results of the study show that AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers with prior wound dur
December 4, 2025